Effect kinetics of desmopressin‐induced platelet retention in healthy volunteers treated with aspirin or placebo

Desmopressin is often used for haemostatic treatment in platelet dysfunction, but the effect kinetics of platelet responses and the mechanism of action are poorly known. This study aimed to determine the kinetics of platelet function responses induced by desmopressin in healthy volunteers treated with aspirin or placebo. Another aim was to correlate platelet responses to changes of von Willebrand factor (vWF) in plasma. We measured platelet function with a glass bead retention test, Ivy bleeding time, vWF:Ag and multimeric structure in plasma. Median baseline platelet retention was 12% (normal reference range 16–27%) during aspirin treatment and 18% during placebo. Median peak platelet retention after desmopressin was 33% during aspirin treatment and 34% during placebo. After about 3 h platelet function had returned to baseline. A second desmopressin dose after 3 h stimulated platelet retention to a similar extent as the first dose. There was no correlation between platelet responses and quantitative or qualitative changes of vWF in plasma. Platelet count did not change significantly. Thus, desmopressin’s effect on platelet function lasts for about 3 h, but may be prolonged by a second dose immediately thereafter. These findings may have important clinical implications for patients with aspirin‐induced platelet dysfunction undergoing surgery.

[1]  I. Nilsson,et al.  Association between factor VIII related antigen and plasminogen activator. , 2009, Acta medica Scandinavica.

[2]  V. Kretschmer,et al.  DDAVP'S Shortening of the Bleeding Time Seems Due to Plasma von Willebrand Factor , 1995, Seminars in Thrombosis & Hemostasis.

[3]  M. Cattaneo,et al.  Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP , 1994, British journal of haematology.

[4]  J. Klimeš,et al.  Simultaneous high-performance liquid chromatographic determination of salicylates in whole blood, plasma and isolated erythrocytes. , 1992, Journal of chromatography.

[5]  S. Lethagen,et al.  DDAVP‐induced enhancement of platelet retention: Its dependence on platelet‐von Willebrand Factor and the platelet receptor GP IIb/IIIa , 1992, European journal of haematology.

[6]  S. Lethagen,et al.  The Effect of DDAVP and Placebo on Platelet Function and Prolonged Bleeding Time Induced by Oral Acetyl Salicylic Acid Intake in Healthy Volunteers , 1992, Thrombosis and Haemostasis.

[7]  T. Wüst,et al.  Influence of different surfactants on the separation of von Willebrand factor multimers by use of agarose gel electrophoresis and semi dry blotting technology. , 1991, Thrombosis research.

[8]  S. Lethagen,et al.  Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. , 1990, Acta chirurgica Scandinavica.

[9]  G. Rock.  A comparison of two methods for the discrimination of VWF:AG multimers. , 1990, Thrombosis research.

[10]  W. Hathaway,et al.  Use of DDAVP in inherited and acquired platelet dysfunction , 1990, American journal of hematology.

[11]  Z. Zeigler.  Platelet glass bead retention is useful in monitoring response to 1‐deamino‐8‐D‐arginine‐vasopressin (d‐DAVP) , 1989, American journal of hematology.

[12]  E. Salzman,et al.  Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. , 1988, Blood.

[13]  J. White,et al.  Shortening of Bleeding Time by 1-Deamino-8-Arginine Vasopressin (DDAVP) in the Absence of Platelet von Willebrand Factor in Gray Platelet Syndrome , 1987, Thrombosis and Haemostasis.

[14]  E. Wenzel,et al.  Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP) , 1986, Thrombosis and Haemostasis.

[15]  J. Sixma,et al.  DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. , 1984, Blood.

[16]  M. Cheang,et al.  SHORTENING OF BLEEDING TIME BY 1-DEAMINO-8-D-ARGININE VASOPRESSIN IN VARIOUS BLEEDING DISORDERS , 1984, The Lancet.

[17]  P. Mannucci,et al.  Response of Factor VIII/von Willebrand Factor to DDAVP in Healthy Subjects and Patients with Haemophilia A and von Willebrand's Disease , 1981, British journal of haematology.

[18]  R. Furlong,et al.  Factor VIII and Fibrinolytic Response to Deamino‐8‐d‐Argenine Vasopressin in Normal Subjects and Dissociate Response in Some Patients with Haemophilia and von Willebrand's Disease , 1980 .

[19]  M. Moia,et al.  DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. , 1989, Blood.

[20]  P. Mannucci,et al.  Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. , 1986, Blood.

[21]  A. Federici,et al.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. , 1982, Blood.